AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32278779
Drug: Inhaled regimens
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled regimens aligning with GOLD recommendations
Trial: 33994285
Drug: Gel support
RxNorm normalized name: CAMPHOR (SYNTHETIC) 2.8 g in 100 g / MENTHOL, UNSPECIFIED FORM 2.25 g in 100 g TOPICAL GEL [Sno Swedish Arctic Gel Support]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gel support surface
Trial: 33530854
Drug: Chia seeds
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chia seeds (40 g/day for 12 weeks)
Trial: 34851445
Drug: Oral triiodothyronine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral triiodothyronine (T3, Tetronine®) 1 μg/kg-body weight/dose every 6 hours for 60 hours
Trial: 34851445
Drug: Oral triiodothyronine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral triiodothyronine (T3) in low-risk patients (Aristotle score < 10.0)
Trial: 34851445
Drug: Oral triiodothyronine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral triiodothyronine (T3) in low-risk patients
Trial: 32878448
Drug: FV-only weekly
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: FV-only weekly vouchers
Trial: 32147519
Drug: Postmastectomy hypofractionated
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postmastectomy hypofractionated radiation therapy (HFRT; 43.5 Gy in 15 fractions over 3 weeks)
Trial: 34068083
Drug: 12-weekly BTA
RxNorm normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12-weekly BTA dosing
Trial: 34068083
Drug: 4-weekly BTA
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 4-weekly BTA dosing
Trial: 34068083
Drug: De-escalation from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: De-escalation from 4-weekly to 12-weekly BTA
Trial: 32628583
Drug: Subcutaneous trastuzumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous trastuzumab
Trial: 36177501
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg tadalafil daily
Trial: 36177501
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg tadalafil 2 hours before sexual relations twice a week
Trial: 36177501
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg tadalafil daily + 15 mg tadalafil 2 hours before sexual relations twice a week
Trial: 32007823
Drug: Renin-angiotensin system
RxNorm normalized name: Renin-angiotensin system inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Renin-angiotensin system inhibitor beyond 1 year
Trial: 32725573
Drug: Codeine phosphate
RxNorm normalized name: Codeine Phosphate
DrugBank: Codeine (DB00318)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Codeine phosphate associated with paracetamol
Trial: 32755802
Drug: Deep brain
RxNorm normalized name: pork brain preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deep brain stimulation (DBS) targeting the ventral anterior limb of the internal capsule
Trial: 35690690
Drug: GHD before
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GHD before treatment
Trial: 35100279
Drug: No injection
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No injection (No pretreatment)
Trial: 33032883
Drug: Steroid-free arm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid-free arm (Basiliximab + Tacrolimus + Azathioprine)
Trial: 33032883
Drug: Steroid arm
RxNorm normalized name: ARM-210
DrugBank: ARM-210 (DB16944)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid arm (Steroid + Tacrolimus + Azathioprine)
Trial: 34275239
Drug: Bismuth-containing quadruple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bismuth-containing quadruple therapy followed by Jing-Hua-Wei-Kang (JHWK) (14 days of quadruple therapy + 30 days of JHWK)
Trial: 34275239
Drug: Bismuth-containing quadruple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bismuth-containing quadruple therapy (14 days)
Trial: 34275239
Drug: All enrolled
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All enrolled patients post-treatment
Trial: 34275239
Drug: Experimental group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental group post-treatment
Trial: 34275239
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group post-treatment
Trial: 32517785
Drug: Blood pressure
RxNorm normalized name: Blood Pressure Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood pressure self-management (daily home blood pressure monitoring and automated medication reduction via telemonitoring)
Trial: 34116351
Drug: LPS challenge
RxNorm normalized name: LP-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LPS challenge (0.4 mg/kg)
Trial: 34116351
Drug: LPS challenge
RxNorm normalized name: LP-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LPS challenge (0.1, 0.2, and 0.8 mg/kg)
Trial: 34409620
Drug: Nasal treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal treatment using pure oxybuprocaine gel with adequate lubrication (group G)
Trial: 34409620
Drug: 1% ephedrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% ephedrine in addition to oxybuprocaine gel with adequate lubrication (group EG)
Trial: 35766039
Drug: Continuous care
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous care combined with optimized insulin injection techniques
Trial: 34130395
Drug: Robenacoxib 2
RxNorm normalized name: robenacoxib 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Robenacoxib 2 mg/kg IM
Trial: 35283454
Drug: Quadruple low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadruple low calcineurin inhibitor (CNI) regimen
Trial: 33878772
Drug: Caffeine treatment
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine treatment in the first 24 hours (group 1)
Trial: 33878772
Drug: Caffeine treatment
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine treatment at the 72nd hour (group 2)
Trial: 34992346
Drug: AD-206 (esomeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AD-206 (esomeprazole 20 mg or 40 mg + calcium carbonate 600 mg)
Trial: 35797000
Drug: Underwater walking
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Underwater walking therapy
Trial: 35654466
Drug: Standard (reactive)
RxNorm normalized name: Stangard
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard (reactive) induction therapy with ixazomib, lenalidomide, and dexamethasone (IRD)
Trial: 35654466
Drug: Frailty-adjusted (adaptive)
RxNorm normalized name: ADAPT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frailty-adjusted (adaptive) induction therapy with ixazomib, lenalidomide, and dexamethasone (IRD)
Trial: 35654466
Drug: Maintenance treatment
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance treatment with lenalidomide+ixazomib
Trial: 35654466
Drug: Maintenance treatment
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance treatment with lenalidomide+placebo
Trial: 32597373
Drug: Challenge condition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Challenge condition (n=40) received daily emails for 24 days highlighting a particular strength, its value, implementation strategies, and a motto.
Trial: 32597373
Drug: Control condition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control condition (n=35) received daily emails containing only the motto for each strength for 24 days.
Trial: 33607813
Drug: Ketorolac plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac plus Lidocaine (30 mg Ketorolac and 2% Lidocaine - adrenaline)
Trial: 33090904
Drug: Exposure to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure to biological dust
Trial: 34873023
Drug: PENG group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PENG group (20 mL 0.5% ropivacaine)
Trial: 34873023
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group (20 mL saline)
Trial: 35711147
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation (3 mg/kg)
Trial: 35711147
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation (4 mg/kg)
Trial: 35711147
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation (6 mg/kg)
Trial: 35711147
Drug: Reference voriconazole
RxNorm normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reference voriconazole (3 mg/kg)
Trial: 35711147
Drug: Reference voriconazole
RxNorm normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reference voriconazole (4 mg/kg)
Trial: 35711147
Drug: Reference voriconazole
RxNorm normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reference voriconazole (6 mg/kg)
Trial: 32574009
Drug: Tretinoin cream
RxNorm normalized name: Tretinoin Cream
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tretinoin cream (0.025%, 0.05%, 0.1%)
Trial: 35684089
Drug: Whey protein
RxNorm normalized name: Whey protein
DrugBank: Whey (DB18685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey protein (25 g) and Vitamin D3 (4000 IU) before bedtime
Trial: 35684089
Drug: Whey protein
RxNorm normalized name: Whey protein
DrugBank: Whey (DB18685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey protein (25 g) and Vitamin D3 (4000 IU) after sleeping
Trial: 35684089
Drug: Maltodextrin placebo
RxNorm normalized name: Maltodextrin
DrugBank: Maltodextrin (DB12583)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maltodextrin placebo (5 g) - Control group
Trial: 35107694
Drug: Higher intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Higher intervention dosage
Trial: 35318229
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Methotrexate and Adalimumab
Trial: 32178640
Drug: Therapist guided
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapist guided internet-delivered cognitive therapy (TG-iConquerFear)
Trial: 32178640
Drug: Augmented treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Augmented treatment as usual (aTAU)
Trial: 33276704
Drug: LT4/LT3 combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LT4/LT3 combination therapy
Trial: 35126618
Drug: nano‐Pueraria targeted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nano‐Pueraria targeted preparation + Tuina therapy
Trial: 35153118
Drug: Cold water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold water spray (0.4 mL per application, twice every hour)
Trial: 35153118
Drug: Cold saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold saline spray (0.4 mL per application, twice every hour)
Trial: 35153118
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (water at room temperature, 1-2 mL using a syringe)
Trial: 32898082
Drug: Topical vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical vancomycin powder at wound closure
Trial: 34153729
Drug: Intravenous methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous methylprednisolone (MP) 40 mg twice daily for 7 days
Trial: 34153729
Drug: Intravenous methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous methylprednisolone (MP) plus tocilizumab (400 mg single dose)
Trial: 33566105
Drug: Personalized weekly
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Personalized weekly coupons with nutrition education during the intervention period (A)
Trial: 33566105
Drug: Personalized weekly
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Personalized weekly coupons with nutrition education during the crossover intervention period (A)
Trial: 32461420
Drug: 0.5% CMC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% CMC + 2000 IU vitamin D through buccal spray (Group B)
Trial: 32461420
Drug: 0.5% CMC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% CMC + 2000 IU vitamin D through buccal spray + 0.05% cyclosporine (Group C)
Trial: 36368748
Drug: Culturally adapted
RxNorm normalized name: casein, emmental cultured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Culturally adapted cognitive behavioural therapy in a group setting (CA-CBT+)
Trial: 32076819
Drug: Oxytocin (24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxytocin (24 international units, intranasal application)
Trial: 34431029
Drug: Acupuncture combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture combined with antidepressants for 3 weeks
Trial: 34431029
Drug: Antidepressants monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressants monotherapy for 3 weeks
Trial: 36331670
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg morphine sulfate ODT
Trial: 36331670
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg morphine sulfate ODT
Trial: 36331670
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg morphine sulfate tablet (Sevredol®)
Trial: 36331670
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg morphine sulfate tablet (Sevredol®)
Trial: 36331670
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg morphine sulfate capsule (Actiskenan®)
Trial: 36331670
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg morphine sulfate solution (Oramorph®)
Trial: 36331670
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg and 10 mg ODTs and tablets
Trial: 34226073
Drug: Nebulized ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized ketamine 0.75 mg/kg
Trial: 34226073
Drug: Nebulized ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized ketamine 1 mg/kg
Trial: 34226073
Drug: Nebulized ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized ketamine 1.5 mg/kg
Trial: 33140457
Drug: PHY906 plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PHY906 plus capecitabine (750 mg/m2 capecitabine b.i.d. for 14 days and 800 mg of PHY906 b.i.d. on days 1–4 and days 8–11 every 21-day cycle)
Trial: 35049373
Drug: 3% diquafosol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% diquafosol ophthalmic solution, 1 drop, 6 times per day for 4 weeks
Trial: 33045402
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 (loading dose, then 3200 IU/day)
Trial: 33106180
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of metoclopramide, ceftriaxone, and paracetamol
Trial: 35482522
Drug: School-based interventions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: School-based interventions (including cognitive behavioural therapy)
Trial: 35482522
Drug: Cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioural therapy (CBT) based interventions
Trial: 33070053
Drug: Gefitinib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gefitinib plus olaparib (250 mg gefitinib daily + 200 mg olaparib three times daily)
Trial: 33070053
Drug: Gefitinib alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gefitinib alone (250 mg daily)
Trial: 35473740
Drug: Low-dose prophylactic
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose prophylactic anticoagulation (PA)
Trial: 35473740
Drug: High-dose prophylactic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose prophylactic anticoagulation (HD-PA)
Trial: 35473740
Drug: Low-dose PA,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose PA, HD-PA, or TA (combined)
Trial: 34286397
Drug: Omega-3 fatty
RxNorm normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 fatty acids capsule along with standard care
Trial: 34255034
Drug: 15 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 μg cholecalciferol daily for 12 weeks (with UVB exposure)
Trial: 34255034
Drug: 15 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 μg cholecalciferol daily for 12 weeks (without UVB exposure)
Trial: 34255034
Drug: 15 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 μg cholecalciferol (both groups)
Trial: 34255034
Drug: 15 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 μg cholecalciferol
Trial: 35760910
Drug: Solifenacin 5
RxNorm normalized name: solifenacin 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solifenacin 5 mg daily
Trial: 33059607
Drug: Vi-diphtheria toxoid
RxNorm normalized name: DIPHTHERIA TOXOID
DrugBank: Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (DB10584)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vi-diphtheria toxoid typhoid conjugate vaccine (Vi-DT)
Trial: 33059607
Drug: Vi-polysaccharide vaccine
RxNorm normalized name: Typhoid Vi polysaccharide vaccine
DrugBank: Typhoid Vi polysaccharide vaccine (DB10803)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vi-polysaccharide vaccine (Vi-PS)
Trial: 36443713
Drug: 82Rb PET/CT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 82Rb PET/CT after amino acid-infusion
Trial: 36443713
Drug: 82Rb PET/CT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 82Rb PET/CT before amino acid-infusion (baseline)
Trial: 36117055
Drug: Oral treprostinil
RxNorm normalized name: Treprostinil
DrugBank: Treprostinil (DB00374)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral treprostinil (TRE)
Trial: 35340949
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg nalbuphine (group N)
Trial: 35340949
Drug: 25 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 μg fentanyl (group F)
Trial: 32172198
Drug: Korean red
RxNorm normalized name: Korean ginseng root
DrugBank: Ginseng (DB01404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Korean red ginseng (KRG) 2000 mg/day
Trial: 32594478
Drug: Internet Behavior
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet Behavior Therapy (IBT, n=51)
Trial: 35685573
Drug: Tamsulosin (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin (0.4 mg/day for eight weeks)
Trial: 35685573
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received standard treatment for analgesia (oral diclofenac 75 mg/12 h as needed)
Trial: 34770611
Drug: Concurrent visual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent visual feedback
Trial: 34770611
Drug: Removal of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Removal of concurrent feedback
Trial: 34770611
Drug: Concurrent vs
RxNorm normalized name: VS-4718
DrugBank: VS-4718 (DB15273)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent vs Terminal feedback
Trial: 32833475
Drug: Cognitive bias
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive bias modification training (CBMT) intervention delivered via an 8-session, at-home, electronic tablet.
Trial: 34664109
Drug: 120 mg
RxNorm normalized name: papain 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg CBD, 5.4 mg THC, and 6.6 mg CBC daily
Trial: 34664109
Drug: 240 mg
RxNorm normalized name: aspirin 240 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 240 mg CBD, 10.8 mg THC, and 13.2 mg CBC daily
Trial: 34664109
Drug: 360 mg
RxNorm normalized name: aspirin 360 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 360 mg CBD, 16.2 mg THC, and 19.8 mg CBC daily
Trial: 34664109
Drug: 480 mg
RxNorm normalized name: magaldrate 480 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 480 mg CBD, 21.6 mg THC, and 26.4 mg CBC daily
Trial: 34664109
Drug: All doses
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All doses of CBD, THC, and CBC
Trial: 32600393
Drug: Histamine-2 receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Histamine-2 receptor antagonist (H2RA)